Last updated: 2026-09-09 19:20:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
BioVie, Inc. (BIVI) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.96, with a market capitalization of $16.90M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.82 to $3.79. This page covers its latest market performance, valuation, price trends and company information.
$16.90M | |
$2.11 | |
$4,609.77 | |
$0.82 | |
$2.07 | |
328.55K | |
4.62M | |
-- | |
$3.79 | |
$0.82 | |
-- | |
-- |
BioVie, Inc. (BIVI) is currently trading at $1.96 as of 2026-09-09 19:19:00, down 5.31% ($0.11) from the previous close of $2.07
During today's regular trading session, BIVI has traded between $0.82 and $4,609.77, with a trading volume of 328.55K shares. The current price is near the lower end of today's range.
Over the past seven days, BioVie, Inc. (BIVI) moved from $2.16 to $1.96, representing a decline of 9.26% ($0.20).
The stock traded between $1.91 and $2.49 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 558.74 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 38.4%
BIVI is currently trading at $1.96, placing it 38.4% of the way from its 52-week low of $0.82 to its 52-week high of $3.79. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 13 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of BioVie, Inc. (BIVI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.